Tech Company Financing Transactions
Neumirna Therapeutics Funding Round
Neumirna Therapeutics, based in Copenhagen, scored $20.5 million from Angelini Ventures, Invivo Capital and Innovestor.
Transaction Overview
Company Name
Announced On
1/8/2025
Transaction Type
Venture Equity
Amount
$20,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support clinical development of its lead asset NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, as well as expand its R&D capabilities and scale its pioneering drug discovery platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Copenhagen, Undisclosed
Denmark
Copenhagen, Undisclosed
Denmark
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Neumirna Therapeutics, a Copenhagen, Denmark-based RNA-focused biotech company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Janine Erler
Founder
Lars Christiansen
Founder
Sakari Kauppinen
Founder
Henrik Klitgaard
Browse more venture capital transactions:
Prev: 1/8/2025: Qualified Health venture capital transaction
Next: 1/8/2025: Deus Robotics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs